ZA200601800B - Novel piperidine-substituted indoles- or heteroderivatives thereof - Google Patents

Novel piperidine-substituted indoles- or heteroderivatives thereof Download PDF

Info

Publication number: ZA200601800B
Authority: ZA; South Africa
Prior art keywords: alkyl; het; formula; cycloalkyl; compound according
Prior art date: 2003-11-17

Application number

ZA200601800A

Other languages

English (en)

Inventor

Martyres Domnic

Anderskewitz Ralf

Dollinger Horst

Pouzet Pascale

Birke Franz

Bouyssou Thierry

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-17

Filing date

2006-03-02

Publication date

2007-05-30

2006-03-02 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2007-05-30 Publication of ZA200601800B publication Critical patent/ZA200601800B/en

Links

150000001875 compounds Chemical class 0.000 claims description 50
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
125000003118 aryl group Chemical group 0.000 claims description 24
150000003839 salts Chemical class 0.000 claims description 14
102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims description 10
229910052736 halogen Inorganic materials 0.000 claims description 10
101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims description 9
125000000623 heterocyclic group Chemical group 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 4
125000005843 halogen group Chemical group 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
238000000034 method Methods 0.000 claims description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
230000008901 benefit Effects 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims 2
101100533890 Hypocrea jecorina (strain QM6a) sor3 gene Proteins 0.000 claims 1
101100533874 Hypocrea jecorina (strain QM6a) sor5 gene Proteins 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
125000004433 nitrogen atom Chemical group N* 0.000 claims 1
108010021375 phosphatidic acid-beta-lactoglobulin Proteins 0.000 claims 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
125000004432 carbon atom Chemical group C* 0.000 description 19
125000001424 substituent group Chemical group 0.000 description 16
-1 MIP-la Proteins 0.000 description 14
102000009410 Chemokine receptor Human genes 0.000 description 8
108050000299 Chemokine receptor Proteins 0.000 description 8
102000019034 Chemokines Human genes 0.000 description 8
108010012236 Chemokines Proteins 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
102100032367 C-C motif chemokine 5 Human genes 0.000 description 6
108010055166 Chemokine CCL5 Proteins 0.000 description 6
102100032366 C-C motif chemokine 7 Human genes 0.000 description 5
101710155834 C-C motif chemokine 7 Proteins 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
239000011575 calcium Substances 0.000 description 5
125000005842 heteroatom Chemical group 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
239000002932 luster Substances 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
239000001301 oxygen Chemical group 0.000 description 5
239000000651 prodrug Substances 0.000 description 5
229940002612 prodrug Drugs 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
241000894007 species Species 0.000 description 5
102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
102000001902 CC Chemokines Human genes 0.000 description 4
108010040471 CC Chemokines Proteins 0.000 description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
210000003979 eosinophil Anatomy 0.000 description 4
239000000203 mixture Substances 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
229910052717 sulfur Chemical group 0.000 description 4
239000011593 sulfur Chemical group 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 3
102100023702 C-C motif chemokine 13 Human genes 0.000 description 3
101710112613 C-C motif chemokine 13 Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000002015 acyclic group Chemical group 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000002585 base Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 2
101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
102100023698 C-C motif chemokine 17 Human genes 0.000 description 2
108050006947 CXC Chemokine Proteins 0.000 description 2
102000019388 CXC chemokine Human genes 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 2
101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
230000003399 chemotactic effect Effects 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
125000002346 iodo group Chemical group I* 0.000 description 2
239000003446 ligand Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000007170 pathology Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000000126 substance Substances 0.000 description 2
LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
108050005711 C Chemokine Proteins 0.000 description 1
102000017483 C chemokine Human genes 0.000 description 1
102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 1
101710149871 C-C chemokine receptor type 6 Proteins 0.000 description 1
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
101710149858 C-C chemokine receptor type 7 Proteins 0.000 description 1
102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
108010039171 CC cytokine receptor-4 Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108010082548 Chemokine CCL11 Proteins 0.000 description 1
108010083647 Chemokine CCL24 Proteins 0.000 description 1
102100023688 Eotaxin Human genes 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
101000777564 Homo sapiens C-C chemokine receptor type 1 Proteins 0.000 description 1
101000980744 Homo sapiens C-C chemokine receptor type 3 Proteins 0.000 description 1
101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
101001052394 Homo sapiens [F-actin]-monooxygenase MICAL1 Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
229920013631 Sulfar Polymers 0.000 description 1
102100024306 [F-actin]-monooxygenase MICAL1 Human genes 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000007794 irritation Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000004001 thioalkyl group Chemical group 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Hydrogenated Pyridines (AREA)

ZA200601800A 2003-11-17 2006-03-02 Novel piperidine-substituted indoles- or heteroderivatives thereof ZA200601800B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03026170		2003-11-17

Publications (1)

Publication Number	Publication Date
ZA200601800B true ZA200601800B (en)	2007-05-30

Family

ID=34610050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200601800A ZA200601800B (en)	2003-11-17	2006-03-02	Novel piperidine-substituted indoles- or heteroderivatives thereof

Country Status (19)

Country	Link
US (1)	US7544806B2 (fr)
EP (1)	EP1687294B1 (fr)
JP (1)	JP4825679B2 (fr)
KR (1)	KR20060127000A (fr)
CN (1)	CN1882565A (fr)
AR (1)	AR047123A1 (fr)
AU (1)	AU2004291297B2 (fr)
BR (1)	BRPI0416665A (fr)
CA (1)	CA2545261C (fr)
IL (1)	IL175678A (fr)
MX (1)	MXPA06004626A (fr)
MY (1)	MY143862A (fr)
NZ (1)	NZ547314A (fr)
PE (1)	PE20051007A1 (fr)
RU (1)	RU2382037C2 (fr)
TW (1)	TW200526622A (fr)
UY (1)	UY28618A1 (fr)
WO (1)	WO2005049559A2 (fr)
ZA (1)	ZA200601800B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE531706T1 (de)	2005-04-30	2011-11-15	Boehringer Ingelheim Int	Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren
ATE524461T1 (de) *	2006-10-27	2011-09-15	Boehringer Ingelheim Int	Neue substituierte piperidylpropanthiole
EP2079725B1 (fr) *	2006-10-27	2011-12-14	Boehringer Ingelheim International GmbH	Modulateurs ccr3 de pipéridyl-propane-thiol
WO2010129351A1 (fr)	2009-04-28	2010-11-11	Schepens Eye Research Institute	Procédé pour identifier et pour traiter une dégénérescence maculaire liée à l'âge
US10213421B2 (en)	2012-04-04	2019-02-26	Alkahest, Inc.	Pharmaceutical formulations comprising CCR3 antagonists
US12221463B2 (en)	2020-08-07	2025-02-11	The Board Of Regents Of The University Of Oklahoma	Method of promoting wound healing by inhibiting CCR3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2533924A1 (fr) *	1982-10-05	1984-04-06	Roussel Uclaf	Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
US5521197A (en)	1994-12-01	1996-05-28	Eli Lilly And Company	3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
US5576321A (en) *	1995-01-17	1996-11-19	Eli Lilly And Company	Compounds having effects on serotonin-related systems
AU729415B2 (en) *	1996-07-12	2001-02-01	Millennium Pharmaceuticals, Inc.	Chemokine receptor antagonists and methods of use therefor
US5962473A (en)	1996-08-16	1999-10-05	Eli Lilly And Company	Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
AU4074897A (en)	1996-09-18	1998-04-14	Eli Lilly And Company	A method for the prevention of migraine
AR013669A1 (es) *	1997-10-07	2001-01-10	Smithkline Beecham Corp	Compuestos y metodos
RU2216540C2 (ru) *	1997-11-18	2003-11-20	Тейджин Лимитед	Производные циклических аминов, способ ингибирования
TR200002182T2 (tr) *	1998-01-27	2000-12-21	Aventis Pharmaceuticals Products Inc.	İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
ES2165274B1 (es) *	1999-06-04	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
AU3789901A (en)	1999-12-17	2001-06-25	Bristol-Myers Squibb Company	Antipsychotic heterocycle compounds
US6916822B2 (en) *	2000-02-18	2005-07-12	Meiji Seika Kaisha, Ltd.	Phenoxyalkylamine derivatives useful as opioid δ receptor agonists
IL153605A0 (en) *	2000-07-21	2003-07-06	Lundbeck & Co As H	Indole derivatives useful for the treatment of cns disorders
ES2201899B1 (es) *	2002-04-01	2005-06-01	Almirall Prodesfarma, S.A.	Derivados de la azaindolilpiperidina como agentes antihistaminicos y antialergicos.
US7157471B2 (en) *	2003-08-25	2007-01-02	Boehringer Ingelheim International Gmbh	Haloalkyl- and piperidine-substituted benzimidazole-derivatives
ATE531706T1 (de) *	2005-04-30	2011-11-15	Boehringer Ingelheim Int	Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren

2004
- 2004-11-11 RU RU2006121328/04A patent/RU2382037C2/ru not_active IP Right Cessation
- 2004-11-11 EP EP04818773.6A patent/EP1687294B1/fr not_active Expired - Lifetime
- 2004-11-11 MX MXPA06004626A patent/MXPA06004626A/es active IP Right Grant
- 2004-11-11 WO PCT/EP2004/012775 patent/WO2005049559A2/fr not_active Ceased
- 2004-11-11 CA CA2545261A patent/CA2545261C/fr not_active Expired - Fee Related
- 2004-11-11 KR KR1020067012008A patent/KR20060127000A/ko not_active Abandoned
- 2004-11-11 BR BRPI0416665-5A patent/BRPI0416665A/pt not_active IP Right Cessation
- 2004-11-11 JP JP2006538792A patent/JP4825679B2/ja not_active Expired - Fee Related
- 2004-11-11 AU AU2004291297A patent/AU2004291297B2/en not_active Ceased
- 2004-11-11 CN CNA2004800338440A patent/CN1882565A/zh active Pending
- 2004-11-11 NZ NZ547314A patent/NZ547314A/xx not_active IP Right Cessation
- 2004-11-12 MY MYPI20044731A patent/MY143862A/en unknown
- 2004-11-15 UY UY28618A patent/UY28618A1/es not_active Application Discontinuation
- 2004-11-15 PE PE2004001117A patent/PE20051007A1/es not_active Application Discontinuation
- 2004-11-16 US US10/990,059 patent/US7544806B2/en not_active Expired - Lifetime
- 2004-11-16 TW TW093135011A patent/TW200526622A/zh unknown
- 2004-11-17 AR ARP040104231A patent/AR047123A1/es not_active Application Discontinuation
2006
- 2006-03-02 ZA ZA200601800A patent/ZA200601800B/en unknown
- 2006-05-16 IL IL175678A patent/IL175678A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ547314A (en)	2010-02-26
CA2545261A1 (fr)	2005-06-02
EP1687294B1 (fr)	2014-05-21
IL175678A0 (en)	2006-09-05
RU2382037C2 (ru)	2010-02-20
IL175678A (en)	2012-08-30
US20050153979A1 (en)	2005-07-14
UY28618A1 (es)	2005-06-30
WO2005049559A3 (fr)	2006-04-13
BRPI0416665A (pt)	2007-01-16
JP2007511480A (ja)	2007-05-10
CA2545261C (fr)	2013-07-23
AR047123A1 (es)	2006-01-11
MY143862A (en)	2011-07-15
PE20051007A1 (es)	2005-12-26
US7544806B2 (en)	2009-06-09
CN1882565A (zh)	2006-12-20
JP4825679B2 (ja)	2011-11-30
TW200526622A (en)	2005-08-16
RU2006121328A (ru)	2008-01-10
MXPA06004626A (es)	2006-06-27
AU2004291297A1 (en)	2005-06-02
AU2004291297B2 (en)	2011-06-23
WO2005049559A2 (fr)	2005-06-02
EP1687294A2 (fr)	2006-08-09
KR20060127000A (ko)	2006-12-11

Publication	Publication Date	Title
CA2384240A1 (fr)	2001-04-26	Amines benzyle cycloalkyle comme modulateurs de l'activite du recepteur de la chimiokine
US20040186143A1 (en)	2004-09-23	Lactams as modulators of chemokine receptor activity
US20080132523A1 (en)	2008-06-05	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ZA200601800B (en)	2007-05-30	Novel piperidine-substituted indoles- or heteroderivatives thereof
EP2265584B1 (fr)	2013-06-12	Amides d'hydroxyalcanyle en tant que modulateurs de l'activité de récepteur de chimiokine
JP2011528359A (ja)	2011-11-17	ケモカイン受容体活性のクロメンモジュレーター
JP4934030B2 (ja)	2012-05-16	アルキル−及びピペリジン−置換ベンズイミダゾール誘導体
EP1603899B1 (fr)	2009-08-26	Derives d'uree heterocycliques pour le traitement de la douleur
US8324251B2 (en)	2012-12-04	Cyclic modulators of chemokine receptor activity
JP4783286B2 (ja)	2011-09-28	ハロアルキル置換及びピペリジン置換ベンゾイミダゾール誘導体
US7157471B2 (en)	2007-01-02	Haloalkyl- and piperidine-substituted benzimidazole-derivatives
US20040063779A1 (en)	2004-04-01	1-Phenyl-1,2-diaminoethane derivatives as modulators of the chemokine receptor activity
JP2006515002A (ja)	2006-05-18	ピロリジノヒドロチナゾリン
EP1648888A1 (fr)	2006-04-26	Nouveaux indoles et heteroderives n-substitues par heterobicycloalkanes
EP1545524A2 (fr)	2005-06-29	N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite du recepteurs de chimiokine
CN101410376A (zh)	2009-04-15	作为趋化因子受体活性调节剂的哌嗪基衍生物